-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garsorasib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garsorasib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garsorasib in Non-Small Cell Lung Cancer Drug Details: Garsorasib is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICT-01 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICT-01 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICT-01 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lonafarnib in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lonafarnib in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lonafarnib in Hepatitis D Drug Details: Lonafarnib (Zokinvy) is a synthetic tricyclic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in Ependymoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in Ependymoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in Ependymoma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is an ester...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Musculoskeletal Inflammation – Drugs In Development, 2023
Global Markets Direct’s, ‘Musculoskeletal Inflammation - Drugs In Development, 2023’, provides an overview of the Musculoskeletal Inflammation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Musculoskeletal Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-7008 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HBM-7008 in Solid Tumor Drug Details: Bi-specific monoclonal antibody is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garsorasib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Garsorasib in Non-Small Cell Lung Cancer Drug Details: Garsorasib is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D-0120 in Hyperuricemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-0120 in Hyperuricemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.D-0120 in Hyperuricemia Drug Details:D-0120 is under development for the treatment of hyperuricemia and...